Novocure at Jefferies Conference: Expanding Horizons in Cancer Treatment

Published 04/06/2025, 23:28
Novocure at Jefferies Conference: Expanding Horizons in Cancer Treatment

On Wednesday, 04 June 2025, Novocure Ltd (NASDAQ:NVCR) presented at the Jefferies Global Healthcare Conference 2025, outlining its strategic initiatives to broaden its cancer treatment offerings. The company showcased both promising advancements and challenges in its quest to extend patient survival using Tumor Treating Fields (TTFields). CEO Ashley Cordova emphasized the company’s robust position in glioblastoma (GBM) and its plans to leverage this success to expand into other aggressive cancers.

Key Takeaways

  • Novocure’s foundation in GBM has generated over $600 million in revenue, supporting its pipeline expansion.
  • Positive Phase 3 trial results in pancreatic cancer and brain metastases from non-small cell lung cancer (NSCLC) offer significant growth potential.
  • The company anticipates a sevenfold increase in its total addressable market over the next two years.
  • Regulatory filings for new cancer indications are underway, with product launches expected in 2026.
  • A focus on profitability is highlighted by CFO Christophe Brockman, with new indications expected to drive revenue growth.

Financial Results

  • GBM Revenue: The established GBM business has generated over $600 million.
  • R&D Investment: Novocure invests more than $200 million annually into its research and development pipeline.
  • Cash Generation: The commercial arm could produce approximately $100 million in cash annually without R&D expenditures.
  • TAM Expansion: The company projects a 7x expansion in its total addressable market, driven by de-risked clinical data.
  • Profitability Path: Profitability is contingent on revenue from new indications, with a delay expected due to payer negotiations.

Operational Updates

  • Glioblastoma: Currently, 4,200 patients are receiving therapy, with ongoing trials like TRIDENT and Keynote D58. A new, lighter array for GBM patients is being introduced.
  • Non-Small Cell Lung Cancer (NSCLC): The OptuneLua device is launched in the US and Germany, with approval pending in Japan. The LUNAR-2 trial is assessing TTFields with pembrolizumab for metastatic NSCLC.
  • Brain Metastases: Phase 3 data has shown extended time to intracranial progression, with FDA submission planned for later this year.
  • Pancreatic Cancer: Positive Phase 3 data indicate a survival extension in locally advanced pancreatic cancer. The PANOVA-4 trial is ongoing, and FDA submission preparations are in progress.
  • Product Development: Novocure plans to launch the MyNovaCare app in 2025 and is finalizing a more flexible torso array.

Future Outlook

  • 2025 Objectives: Maintain GBM business, drive OptuneLua launch in NSCLC, and advance pipeline submissions and trials.
  • Near-Term Growth: Brain metastases and pancreatic cancer are expected to significantly boost top-line growth in the next one to two years.
  • Long-Term Vision: The company aims for profitability and continued pipeline investment to address additional solid tumors.

Q&A Highlights

  • Concurrent Treatment: TTFields can be used with other therapies, enhancing treatment effectiveness.
  • Pancreatic Cancer Adoption: Physicians have responded positively to new data, with efforts underway to educate them on device use.
  • Economies of Scale: Existing resources are being leveraged across different indications to optimize efficiency.

For more details, readers are encouraged to refer to the full transcript.

Full transcript - Jefferies Global Healthcare Conference 2025:

Operator: Alright. Are we live? Alright. Well, welcome everybody. And thank you

Ashley Cordova, Chief Executive Officer, Novocure: so very much for coming this afternoon to hear an overview of Novocure. My name is Ashley Cordova. I’m the chief executive officer at Novocure and I’m here today with Christophe Brockman, our CFO. Excited to share an overview of the company with you and also to take any questions that you may have. I’ll start with the standard forward looking disclosure.

We will be making forward looking statements in here. Let me start with what is Novocure? Since day one, Novocure has been focused singularly on one mission. Together with our patients, we are striving to extend survival in some of the most aggressive forms of cancer. We do that through the development and commercialization of tumor treating fields.

Tumor treating fields are electric fields that leverage the electrical properties of dividing cells to kill cancer. And we do this through a variety of mechanisms, which I have shown up here first and foremost. The first and foremost of these mechanisms is the antimitotic mechanism. We know that if we can get an electric field inside a cell that we can actually exert a force at a distance and physically dislocate several of the proteins which are critical to cancer cell division. That includes the tubulin spindle.

It also includes things like the chromosomal furrow. What we also now know is that the way that that cancer cell death is triggered activates the immune system. We see all the classical signs of immunogenic cell death with calreticulin exposure, with ER stress, with the hallmarks of immune activation. And so we now are learning more about the downstream immune activation mechanism as well as things like the inhibition of DNA damage repair and the effect on the tumor microenvironment. We’re able to target specifically cancer cells because the cell membrane acts as a very effective capacitor of electric fields.

And it will filter out fields that are not specifically frequency tuned at the intermediate frequencies we use to treat cancer. So that’s the mechanism, Tumor Treating Fields. And we deliver this therapy through a medical device. There are two key components to this device which are shown here on the screen. The first is the field generator that actually generates the field and it connects to four transducer arrays which are worn.

This is the disposable part of the therapy in the region of treatment. So for patients like you can see on the left here that are using our Optune Geo device for glioblastoma, they’re wearing four transducer rays on their head. And for the OptuneLua patient that you see there on the left, he is wearing transducer rays under his shirt on the torso. We also can treat in the abdomen with the pancreatic data that we’re about to review. We have a solid foundation in glioblastoma where we are NCCN category one, approved and reimbursed with more than four thousand two hundred patients on therapy now actually as of the first quarter, and over $600,000,000 in revenue.

This is our solid foundation that we leverage to invest in the pipeline and bring this therapy to many, many more solid tumors. But what we are standing on here is a well established commercial business with an infrastructure that we’re able to leverage across indications that has been tried and tested. We have a commercial business that if we were to take away the R and D investment, would be generating about $100,000,000 in cash in its own right, which we are then able to put back into the pipeline, again, to the tune of over $200,000,000 a year. And because we are a medical device, we are uniquely positioned with the intellectual property that we have, because we not only have the IP around some of the core mechanisms, but we are also able to patent the evolving medical technology behind the device. So very well positioned on this solid foundation in GBM to bring this cancer to many more solid tumors.

And this is why it’s such an exciting year and such an exciting time to get to know more about Novocure and Tumor Treating Fields. Because we have established this business over the last twenty five years, the science and actually the commercial infrastructure in glioblastoma. But we now have further derisked this with three positive randomized phase three trial readouts in non small cell lung cancer, in brain metastases from non small cell lung cancer, and just this last weekend at ASCO in pancreatic cancer. And so we are truly entering a new era with a platform therapy. And this slide summarizes right here what we’re talking about with this platform.

As you can see, we have four indications which now have proven to provide efficacy for patients in high unmet needs. Glioblastoma is our base business where we extend survival, the best chance for extended long term survival for patients with newly diagnosed GBM. And as I noted, more than six hundred million in revenue there. But we also just launched in The US in non small cell lung cancer. We that FDA approval last October for metastatic non small cell lung cancer post platinum failure.

The launch is going well. We’re in the early stages of that ramp. But we’re in market today in both The US and Germany. And we’re at the regulators in Japan with that indication. We also announced last year positive data in brain mets for non small cell lung cancer.

Again, the first time we’ve ever seen a therapy that extends the time to intracranial progression, which is the key output you’re looking for in the MET. That data will be with the FDA later this year. And pancreatic cancer just this last weekend at ASCO with the first trial ever to extend survival in locally advanced unresectable pancreatic cancer. The data was published this weekend as well and is also preparing for submission to the FDA this year. Both of these we would expect pending approval to be launching next year.

So we are layering on three additional indications to what is already a well established business in GBM. And that opens up a TAM expansion opportunity of 7x over the next two years with fully derisked clinical data. So GBM business alone, again, established commercial business with more than $600,000,000 in revenue and a TAM expansion opportunity in hand over the next six to eight quarters with DERUST clinical data, along with the pipeline potential of the platform that we continue to invest in. So we think really an incredible opportunity and the right time to pick up your pencils and do research on the company. Because it is the current event and because it is actually such an incredible data set, I want to spend a minute talking about our pancreatic data.

This was on podium at ASCO this last Saturday. It was also published Saturday morning in the Journal of Clinical Oncology. And what you can see here is the first positive phase three trial results ever in locally advanced pancreatic cancer unresectable. You can see the top line of the Kaplan Meier curve in purple there. That is the extension of survival, a two month extension in median overall survival with the addition of Tumor Treating Fields to the current standard of care, which is gemcitabine and apaclataxol.

And what you can also see is a one year survival rate that went from sixty percent to sixty eight percent, and a very clean separation of the curve, which lasted throughout the duration of treatment. A lot of positive energy buzz. I was in Chicago this week and I will tell you the energy at the booth, the energy in the presentation room, the energy from the discussant, and also the call out of the publication was all very positive. The physicians understand how unique it is to have positive data in this setting. And we’re very excited to see this trial readout.

Published in JCO, selected for best of ASCO, and we are in the final stages of preparing that regulatory filing now to get to the FDA this year. And as I noted, we would anticipate, pending approval, a launch next year. We also continue to invest in the pancreatic cancer indication. And we have a phase two trial, PANOVA four, which we’ll be reading out early next year, which looks at tumor treating fields in metastatic disease with the addition of atezolizumab to the gym Abraxane protocol. And again, this highlights the potential to even further improve outcomes with the immune activation and the IO combination.

We know that when you activate the immune system, you synergize well with PD-1s, and that’s what we’re looking to see empanova for. Beyond just the overall survival, I think what was also resonating so well with the physicians was the extension and pain free survival. Pancreatic cancer is a dismal diagnosis just from an overall survival prognosis, but it is also unfortunately a very painful disease. And the ability to manage the symptoms and the pain is critically important in the treatment journey. So we saw a six month extension in pain free survival when you added Tumor Treating Fields onto the standard of care.

And I will tell you that this particular data point, along with the distant PFS benefit that we also saw, really resonated with physicians and is generating a lot of excitement in the field. So we are also excited about this. And as I noted, we are packaging this data up for the FDA this year, would expect to get it submitted to regulators around the world, and are looking forward to launch in 2026. But we’re not done with pancreatic cancer. This is truly a platform therapy.

And what you see here is a snapshot of our pipeline across solid tumors. The first thing I’ll point to is these are all very aggressive cancers with high unmet need. And that is where we are uniquely positioned because of the physical modality and the device based treatment to go where systemic therapies sometimes have a hard time going. For instance, in glioblastoma, where we have the blood brain barrier, you’re often not able to get effective chemotherapeutic agents into the brain. An electric field can penetrate the blood brain barrier without any problem.

We see a similar situation in the pancreas with the stromal tissue where we are able to enter some of these privileged sites. And again, hopefully with the combination of IO, be able to bring incremental benefit in some of these tumors that have been cold historically to immuno oncology. But what you can see here in our specific research, we’re focused on three clinical harbors. The first is the head where we have the glioblastoma indication. We have an ongoing trial that is, you know, we have the approval on our EF 14 data, which is the significant extension, the best chance for extended long term survival in GBM.

We have two trials that are ongoing there. One which is in the patient follow-up stage. This is the TRIDENT trial, which looks at starting tumor treating fields concurrent with radiation instead of waiting to start post radiation. So can we further extend survival if we begin earlier in the disease state? That trial is fully enrolled.

We’re in the two year follow-up window right now when we would expect to read that data out early next year. We’re also running, opening and enrolling right now our keynote D58 trial in which pembrolizumab is actually the experimental agent. We’re looking at tumor treating fields in temozolomide versus tumor treating fields temozolomide and pembro. Again, looking to leverage the potential to activate the immune system in GBM in a disease state where pembro historically has not shown an extension of overall survival. So we’re very excited about the continued development in the brain.

As I noted, mets, which is lung cancer but treated in the brain, that data is read out. That was positive phase three data where we extended the time to intracranial progression. We will have that with the FDA later this year. And then you can see our pipeline in lung cancer and pancreatic cancer below. In lung cancer, on the back of our LUNAR trial, we are now approved in The US, approved and launched in Germany, and pending approval in Japan.

And we are running another large randomized phase three trial, the LUNAR-two trial, which looks at the protocol that we took in metastatic disease post platinum in LUNAR and moves it first line. So we’re looking at tumor treating fields combined with pembrolizumab for first line metastatic non small cell lung cancer. And I already hit it on the pancreatic trials earlier. The takeaway here is there is a lot going on in this pipeline. This truly is a platform therapy.

We believe that we can effectively extend survival outcomes for any solid tumor that we can surround and get a field inside the tumor bed. And we’re able to fund the research in these indications with the financial strength that’s generated from our existing commercial business in GBM and from the top line growth that will come from our future indications. And it’s a really exciting year. When we look at where we’re going, here are our 2025 objectives. This is a catalyst rich year.

You can see that we are focused on the commercial side, both on sustaining the GBM business, but really driving an effective launch of OptuneLua in non small cell lung cancer, where we’ll be focused on active patient growth both in The US and Germany, and pending the approval and patient growth in Japan. We are focused on advancing the pipeline. I’ve already walked through that here, but we have the successful presentation and publication of the PANOVA three data this last weekend. We will have both PANOVA three and METIS with the FDA later this year. And then we’re in the patient follow-up period for, again, another large randomized trial in GBM and our PANOVA four trial in pancreatic cancer, which we’ll both read out early next year.

And because we are a device, we also have the unique opportunity not only to develop the clinical pipeline, but to invest in product development. And so you can see three key milestones that we’re working on in 2025 on the product side with the launch of the MyNovaCare app and just the evolution of our software ecosystem that supports the device. We are also well through the rollout of a new array for our GBM patients that’s lighter, flexible, and more comfortable to wear. And we’re investing in the final development stages of a lighter, more flexible torso array that will be in market for our torso patients in upcoming years. So a lot of exciting catalysts this year.

We are heads down focused on execution. And we could not be more excited about the opportunity that we have with clinical data de risked in hand to bring this therapy to many more patients with these aggressive tumors that are in desperate need of additional therapeutic options. If I was to summarize the journey on a longer term scale, we are standing on a solid foundation of 4,200 active patients today in GBM. We are focused on these near term opportunities of continued support from the GBM business plus a successful rollout of our OptuneLua launch in lung. Then when we look ahead just one to two more years, we would expect brain mets and pancreatic cancer to be contributing material top line growth.

And then we look beyond that. We’re looking to a path to profitability and continued investment in the pipeline to bring this to as many solid tumors as we can for these patients with aggressive cancers. And with that, I’m going to pause and ask Christophe to come up. We’re both going to go over to the table and take any questions you may have. Alright, thank you.

Unidentified speaker: Yeah, so you mentioned specifically in terms of treatment concurrent, sorry, you mentioned in terms of treatment concurrent with radio or chemotherapy, how much do you see it as a challenge or an opportunity moving up the sort of the treatment path for these patients? Is that an uphill battle for you right now, or is that becoming easier as it’s being established commercially?

Ashley Cordova, Chief Executive Officer, Novocure: So mechanistically, first of all, if we zoom out, we know we can be used in combination with any therapy that we’ve tested so far to date. And if you just think about it, this is a physical modality. It can be used on top of whatever the evolving standard of care is. Right? So we’re uniquely positioned to go on top of whatever is commonly used in any disease state.

So I would say we’re always looking to date with either an additive or a potentially synergistic benefit when we go in combination therapies. And what we know so far in the disease states that we’ve studied so far is that earlier is better. Because at that kind of first domino, we’re an antimitotic, that if you can get ahead of the division rate, you’re going to have a better effect. Right? So a newly diagnosed GBM, for instance, our data is stronger than it was in recurrent.

And that is the hope with the combination of radiation that starting three months earlier, you just get the incremental benefit of of the earlier start. But then there are potential synergies that come from the mechanism itself. So we do also know that beyond the antimitotic effect and beyond the immune activation that we inhibit DNA damage repair. So in our phase two studies to date, we see the real potential to have an extended survival simply because you’re able to limit the ability for the DNA to self repair post radiation when you’re wearing the device concurrently with that radiation treatment. That’s the promise behind Trident.

So, you know, at kind of the worst case, we’re going to get the additional three months because we start earlier and you just get an extended, you know, duration of therapy in those three months. But the potential is that we’re actually able to make the radiation much better. And that’s what we’ll see when that trial reads out next year.

Unidentified speaker: So when you mentioned that trial, that was in pancreatic specifically, or are you now looking at all the the solid tumor indications with regards to moving it upstream?

Ashley Cordova, Chief Executive Officer, Novocure: So Trident is specifically a newly diagnosed GBM that’s concurrent with radiation. The pancreatic cancer trial, which is concurrent with atezolizumab, which is Roche’s IO, is in metastatic, so a later line of therapy in pancreatic cancer.

Unidentified speaker: And with different call points, you think you’ll be able to leverage your springboard off glioblastoma and the other indications?

Ashley Cordova, Chief Executive Officer, Novocure: Definitely. Definitely. We have a sales force built up for medical oncologists with the OptinLua launch. We think we’ll be able to leverage that field force for the pancreatic cancer indication. Similarly with Metis, our brain mets indication, the field force that’s calling on GBM docs should be well positioned there.

Anything? Christophe’s here? All right, if no questions I can talk, I can wax and wane even more about the benefit of our pancreatic cancer indication. And I think that’s maybe worth spending a moment for those on the webcast because we’re getting a lot of questions, I would say, about how we think this will be adopted in So let me actually plant with myself that same question and then maybe, Kristoff, I’ll plant with you about how we think the path to profitability.

Because I will say those are two of the questions that we are hearing a lot, right? So first of all, this pancreatic data is meaningful. As I said, I was at Chicago this last weekend and it was honestly really fun because the buzz was there. The physicians are reacting very well to this data. They have not seen positive survival in pancreatic cancer in this locally advanced setting.

In the unresectable locally advanced setting, they’ve never seen it, right? And they’re just not used to these positive clean Kaplan Meier curves. And again, the extension in pain free survival is really resonating as well. So for the physicians that were coming up, the types of questions we were getting are how can I get the experience and the awareness of how to incorporate this device into my practice? Not whether or not the data’s strong or whether or not this, you know, it clearly provides a benefit.

And the questions are now how do I learn about how to use this device? And this is where the established GBM commercial business provides a really good platform upon which we can launch. Because first of all, we know how to do this. We have a team of device support specialists that actually deliver the device to the patient, they train the patient in their home, and they’re actually there to provide technical support, not medical support, but really technical support for any questions that the patient may have along the treatment journey throughout their treatment of care. And they’re also helping them monitor their usage because there’s no half life to an electric field, we say.

So we know that for it to be working, the device has to be on and usage is important. We take care of all of that. We also take care of the billing and the revenue operation side for the physician. So it is not a burden on the physician’s practice, but the physician itself has to learn that. Right?

They have to go through that first prescription and get the experience with actually how the start happens. They send the script to us, and then they need to get you know, they need to learn that system. But I’ll I’ll mention again, we know how to do this, those physicians, once they have that positive first experience, become kind of a well of support amongst the community to say, I’ve tried it, and I know how it’s it’s working, and it’s quite easy, and their support staff is great. And and, you know, that that’s really our awareness and an adoption opportunity, I will say. I won’t even say challenge, because we’re able to leverage what we’ve done in GBM.

We’re able to leverage the radiation oncologist on the tumor board to help spread that word. And that’s the work that pending approval at the FDA in pancreatic cancer will be out sharing with all the physicians. Not just the data, but how easy it is for them to get these patients started on the device and for the patients to incorporate it. And actually, the quality of life benefit that the patients see as well. So this is counterintuitive because the patients have to integrate a device into their life.

But because we are keeping the disease at bay and we are doing so much to manage the pain, the quality of life of these patients does does go up, and we see a benefit in global health status. So I think that’s really the opportunity and our, you know, the work of our teams to make sure that patients, physicians are able to understand and that patients are able to talk to other patients about how they incorporate this in the device. We’re doing this today in lung cancer and, you know, we’ll replicate that same model in pancreatic and mets. I pre planted a question to you about what about profitability?

Christophe Brockman, Chief Financial Officer, Novocure: I will talk about profitability in a minute and I will just emphasize a little bit to what you said actually. Because I was sort of on the other side and looking externally at the company not too long ago. What I saw is basically a company coming from one indication, being in one indication commercially for ten years and now having the opportunity with clinically de risked data to approach three new indications. What I underestimated how much value there is in the strength of the base business that we have. We do $600,000,000 in revenue last year, you look at last year, right?

We still have growth in this business. It’s a complex business across a couple of countries and I’d you know, this is a really robust capability underlying. In particular, you know, field force is maybe something that more companies have, but the device specialists that we have that basically work directly with patients, that’s a fairly unique capability, as well as the revenue operations team that we have, the reimbursement team that works directly with payers is also a very strong capability and it’s very clear it’s not being built in one or two years. This is sort of pressure tested and really, I would say, a very well working machine. Now to profitability, first I’d say it’s something that we’re very focused on.

We have a path to profitability. We see the value in profitability and what we need is additional contributions from the new indications. So because we are in the device world and not in the pharma world, there is always a lag in terms of the revenue coming in from launching the new indications. And what we said on the lung launch, which will be true for the other launches as well, is because we will have to work on getting the new indication on medical policies from a payer perspective as well as get Medicare coverage. It will take us about a year to work with commercial payers and about another year to work with Medicare to get more standardized approval for our therapies.

And what that means is that this year we are in a demand generation year for the lung launch and we expect more material contributions from a revenue perspective next year. And then when we launch or that’s our expectation, obviously, pending approval, when we launch the other indications next year, we will have the revenue contributions coming in with a year lag. But from that perspective, this year is really a transition year and then next year we expect sort of from the new indications more material revenue contributions to hit our revenue line and that is basically providing us the path

Ashley Cordova, Chief Executive Officer, Novocure: for profitability. I mean this is the power of layering on the additional indications, right? Demand generation this year in lung, top line growth next year from the lung indication, and that then fuels the flywheel. And we really do think it will become a flywheel of kind of bring on each, the demand generation of each additional new indication will generate that top line growth which will flow to the bottom line which we can then reinvest back into the pipeline and keep the flywheel going. So when

Unidentified speaker: I asked earlier about sort of spring boarding or leveraging little less NOLA, but now with regards to profitability, are there real economies of scope and scale as you expand in other indications? And where are those manufacturing, regulatory, what?

Ashley Cordova, Chief Executive Officer, Novocure: Yeah. Can Yeah. Definitely.

Christophe Brockman, Chief Financial Officer, Novocure: Mean Yeah. Yeah. We we have I mean, first of all, the capability we talked about, you know, that are established. We have a field force where we build a separate field force for now our indication in non small cell lung cancer. That has been built.

That will also be the field force that we will use for the pancreatic cancer launch. And similar, and you mentioned that before, on the GBM side we have a field force and they will also then take on a brain metastasis. That’s one thing. Now the revenue reimbursement team that we have, the more claims we’ll have, I mean there is some growth to be expected, but there is significant economies of scale as well as on the device service specialist team. On these core capabilities as well as when we think more broadly on our SG and A spend, we expect significant economies of scale.

Ashley Cordova, Chief Executive Officer, Novocure: The only other thing I would maybe add there is the geographic overlay. We’re talking indications right now, but we’re also well established in all the kind of developed, you know, high value paying commercial markets. And so you only have to build that once. Know, it does, there’s a lot of economies of scale. We’re direct in every market that we are in with the exception of China where we partner with Zai Labs.

We’re direct in Japan. And we are, you know, well established, as I said, in kind of the large markets in Western Europe and Japan that you would expect to be repaying for high bio oncologics. Yeah. I mean, it’s a guys, we’re we’re biased, but we think there’s really such an incredible opportunity here. We know that we have the data in hand, and we’re at just the right moment.

And and I think that’s our message to everybody listening is now is the time to pick up your pencils here because these catalysts are gonna come fast and furious. And we’re committed to, you know, be heads down and and execute against them.

Christophe Brockman, Chief Financial Officer, Novocure: Thank you very

Operator: much.

Ashley Cordova, Chief Executive Officer, Novocure: Alright. Thank you.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.